Cotinga Pharmaceuticals año OPV
¿Qué es el año OPV de Cotinga Pharmaceuticals?
El año OPV de Cotinga Pharmaceuticals, Inc. es 2007
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en TSXV en comparadas con Cotinga Pharmaceuticals
¿Qué hace Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Empresas con año opv similar a Cotinga Pharmaceuticals
- G3 Exploration tiene año OPV de 2006
- Evolis SA tiene año OPV de 2006
- Unity Infraprojects tiene año OPV de 2006
- News Invest tiene año OPV de 2006
- AuStar Gold tiene año OPV de 2006
- Sky and Space Global tiene año OPV de 2006
- Cotinga Pharmaceuticals tiene año OPV de 2007
- Manas Resources tiene año OPV de 2008
- Mastech Digital Inc tiene año OPV de 2008
- MYR Inc tiene año OPV de 2008
- Dana Inc tiene año OPV de 2008
- American Water Works Co tiene año OPV de 2008
- Chromadex Corp tiene año OPV de 2008